Hyperfine, Inc. (HYPR)
| Market Cap | 58.33M |
| Revenue (ttm) | 11.03M |
| Net Income (ttm) | -44.24M |
| Shares Out | 72.01M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,914 |
| Open | 0.830 |
| Previous Close | 0.819 |
| Day's Range | 0.800 - 0.885 |
| 52-Week Range | 0.795 - 3.280 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 2.12 (+161.73%) |
| Earnings Date | May 9, 2024 |
About HYPR
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut. [Read more]
Financial Performance
In 2023, Hyperfine's revenue was $11.03 million, an increase of 61.90% compared to the previous year's $6.81 million. Losses were -$44.24 million, -39.54% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for HYPR stock is "Buy." The 12-month stock price forecast is $2.12, which is an increase of 161.73% from the latest price.
News
Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. at ISMRM with 17 abstracts assessing the potential of using Swoop® System images across multiple care settings and clinical conditions.
Leading Institutions Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
GUILFORD, Conn.--(BUSINESS WIRE)--Leading institutions enroll first Alzheimer's patients receiving amyloid-targeting therapy in CARE PMR study.
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable ma...
Hyperfine, Inc. Collaborates with King's College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. collaborates with King's College London to demonstrate the Swoop® system and UNITY Project to The Princess Royal.
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to announce fourth quarter and full year 2023 financial results on March 21, 2024.
Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to present at the Oppenheimer 34th Annual Healthcare Conference.
Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes
GUILFORD, Conn. & ORLANDO, Fla.--(BUSINESS WIRE)--Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes.
Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. presents data at 2024 International Stroke Conference and provides an update on enrollment in ACTION PMR stroke observational study.
Hyperfine, Inc. Launches AI-powered Brain Imaging Software for Enhanced Image Quality and Ease of Use
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. launches AI-powered brain imaging software for enhanced image quality and ease of use.
Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces presentations on clinical advancements at RSNA 2023.
Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to present at the Piper Sandler 35th annual healthcare conference.
Hyperfine, Inc. Reports Third Quarter 2023 Financial Results
GUILFORD, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world's first FDA-cleared, portab...
Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO Patients
GUILFORD, Conn.--(BUSINESS WIRE)--Observational study finds that Hyperfine, Inc. portable MR brain imaging system assists clinicians in early detection of ABI in ECMO patients.
Hyperfine, Inc. to Announce Third Quarter Financial Results on November 9, 2023
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to announce third quarter financial results on November 9, 2023.
Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces promotions of two key clinical affairs executives.
Hyperfine, Inc. Receives FDA Clearance for Updated AI-powered Software with Improved Image Quality for All Swoop® System Sequences
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. receives FDA clearance for updated AI-powered software with improved image quality for all Swoop® system sequences.
Hyperfine, Inc. to Present at Gilmartin Group Emerging Growth Showcase
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance br...
Hyperfine, Inc. Reports Second Quarter 2023 Financial Results
GUILFORD, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, poi...
Enrollment Completed for HOPE PMR Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable MR Imaging® System
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance br...
Hyperfine, Inc. to Announce Second Quarter Financial Results on August 14, 2023
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™, today an...
Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D. to Chief Operating Officer
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance br...
Hyperfine, Inc. Launches Observational Study to Define New Imaging Paradigm in Stroke Care
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance br...
Hyperfine, Inc. and the International Society for Magnetic Resonance in Medicine Collaborate to Enhance Global Access to MR Education
TORONTO--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imag...
Hyperfine, Inc. Receives Grant for an Additional Three Years to Utilize Innovative Swoop® Portable MR Imaging® System in Low and Middle-Income Countries
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance im...
Hyperfine, Inc. Reports First Quarter 2023 Financial Results
GUILFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, poin...